LEO 124249 Ointment in the Treatment of Alopecia Areata

LEO Pharma

Status and phase

Completed

Phase 2

Conditions

Alopecia Areata

Treatments

Other: Vehicle

Drug: LEO 124249

Study type

Interventional

Funder types

Industry

Identifiers

NCT02561585

EXP-1222

Details and patient eligibility

About

This clinical trial attempts to investigate the efficacy and safety of LEO 124249 ointment in the treatment of alopecia areata and the molecular disease mechanism and biomarkers.

Full description

The objectives of this clinical trial are to compare the efficacy of twice-daily topical LEO 124249 30 mg/g ointment with LEO 124249 ointment vehicle for 12 weeks in the treatment of hair loss in subjects with alopecia areata, to evaluate the safety of this treatment, to evaluate hair regrowth, to determine subject quality of life, and to explore disease mechanism and its biomarkers.

Enrollment

40 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Subjects must have signed and dated informed consent after receiving verbal and written information about the clinical trial.
Subjects with unequivocal clinical diagnosis of moderate to severe scalp alopecia areata (patch type, totalis, universalis), as determined by the (sub) investigator, affecting a minimum of 30% scalp area at Visit 1 (Screening) and Visit 2 (Day 1, baseline).
Minimum 6 month duration of hair loss at Visit 1 (Screening). No upper limit time limit.
Subject must accept to not cut hair in the treated scalp areas during the trial.

Exclusion criteria

Females who are pregnant or are breast feeding.
Current signs of spontaneous hair regrowth.
Diffuse type alopecia areata.
Co-existing moderate to severe androgenic alopecia (Norwood-Hamilton stage IV-VI and Ludwig stage II and III)
Subjects with changed or expected changes in medication for thyroid disease within 6 month before Visit 1 (screening) or during the trial.
Systemic treatment with immunosuppressive drugs (e.g. methotrexate, cyclosporine, azathioprine), chloroquin derivatives, corticosteroids, or any other systemic therapy that in the opinion of the investigator could affect hair regrowth, within 6 weeks prior to randomization (inhaled or intra-nasal steroids corresponding to up to 1 mg prednisone for asthma or rhinitis may be used).